

Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations

Daniel J. Panyard¹, Kyeong M. Kim², Burcu F. Darst³, Yuetiva K. Deming^{1,4,5}, Xiaoyuan Zhong⁶,
Yuchang Wu⁶, Hyunseung Kang⁷, Cynthia M. Carlsson^{4,5,8}, Sterling C. Johnson^{4,5,8}, Sanjay
Asthana^{4,5,8}, Corinne D. Engelman^{1†}, Qiongshi Lu^{6,7†}

¹Department of Population Health Sciences, University of Wisconsin-Madison

²Department of Biotechnology, Yonsei University

³Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California

⁴Wisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison

⁵Department of Medicine, University of Wisconsin-Madison

⁶Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison

⁷Department of Statistics, University of Wisconsin-Madison

⁸William S. Middleton Memorial Veterans Hospital

†Denotes joint senior authors

Summary

Advances in technology have allowed for the study of metabolomics in the context of disease, enabling the discovery of new potential risk factors, diagnostic markers, and drug targets. For neurological and psychiatric phenotypes, the cerebrospinal fluid (CSF) is of particular biomedical importance as it is in direct contact with the brain and spinal cord. However, the CSF metabolome is difficult to study on a large scale due to the relative complexity of the procedure needed to collect the fluid compared to blood or urine studies. Here, we present a metabolome-wide association study (MWAS), an analysis using individual-level genetic and metabolomic data from two cohorts to impute metabolites into large samples with genome-wide association summary statistics. We conducted a metabolome-wide genome-wide association analysis with 338 CSF metabolites, identifying 16 genotype-metabolite associations, 6 of which were novel. Using these results, we then built prediction models for all available CSF metabolites and tested for associations with 27 neurological and psychiatric phenotypes in large cohorts, identifying 19 significant CSF metabolite-phenotype associations. Our results demonstrate the potential of MWAS to overcome the logistic challenges inherent in cerebrospinal fluid research to study the role of metabolomics in brain-related phenotypes and the feasibility of this framework for similar studies of omic data in scarce sample types.

Introduction

In recent years, the study of metabolomics has yielded novel insights into a variety of complex diseases, including diabetes¹, obesity², cancer³, and Alzheimer's disease (AD)⁴. The identification of disease-associated metabolites can shed light on mechanisms contributing to disease and reveal biomarkers that can be used for diagnosis and prognosis.

To date, most metabolomics studies in humans have focused on more accessible sample types like blood or urine. However, for psychiatric and nervous system disorders, the cerebrospinal fluid (CSF) is of particular relevance^{5,6}. CSF is in direct contact with the brain and spinal cord and separated from the blood by the blood-brain barrier; as such, CSF may more directly reflect physiological changes occurring in the central nervous system (CNS) than other sample types. In AD, for example, CSF is the source of some of the most powerful biomarkers for disease onset and progression, including amyloid-beta (A β) and phosphorylated tau⁷.

The difficulty in studying the CSF metabolome is that acquiring CSF samples is more challenging than blood or urine samples, requiring a lumbar puncture (LP), thus making CSF samples a rare and valuable resource, particularly those from healthy volunteers. This small sample size, however, makes the detection of changes in the CSF metabolome during disease progression a logistic and statistical challenge. Transcriptome-wide association studies (TWAS) have been a successful approach to dealing with such issues for gene expression⁸. Using a reference panel of genotype and gene expression measurements to model the regulatory machinery of the genetically regulated component of gene expression, TWAS allows for the estimation of potentially causal gene-disease associations in data sets where only genetic information is present, circumventing the need to collect gene expression data with every disease-focused data set⁹. TWAS and related methods have been successfully used with a diversity of phenotypes, including autoimmune diseases⁹, schizophrenia¹⁰, and AD¹¹.

Building on the success of TWAS, we demonstrate the feasibility of a metabolome-wide association study (MWAS) that combines the richness of a scarce resource study (e.g., a CSF metabolome study) with the accessibility and scale of large, publicly available genome-wide association study (GWAS) summary statistics. We conducted the first CSF metabolome-wide GWAS and then used the results to build CSF metabolite prediction models from genetic information to study the association of CSF metabolites with a variety of brain-related phenotypes using GWAS summary statistics.

Methods Overview

The general outline of our MWAS approach is as follows: 1) identify single nucleotide polymorphism (SNP)-metabolite associations; 2) build metabolite prediction models using genotypes; 3) impute and test metabolite-phenotype associations with publicly available GWAS summary statistics.

The primary data for this study came from two different longitudinal cohort studies of AD with available CSF metabolomics and genotype data: the Wisconsin Alzheimer's Disease Research

Center (WADRC) and Wisconsin Registry for Alzheimer's Prevention (WRAP) studies^{12,13}. To improve the generalizability of this analysis, only data from cognitively healthy participants were used. Imputation and stringent quality control were performed on both the CSF metabolite and genotype data, resulting in a final data set of 291 baseline visits of unrelated European-ancestry individuals with 338 CSF metabolites (Supplementary Tables 1-2).

SNP-metabolite associations were estimated using GWAS conducted on both WADRC (discovery) and WRAP (replication). Both GWAS results were then meta-analyzed to maximize statistical power. Genome-wide prediction models were built for each CSF metabolite with independent SNPs as predictors, using both penalized regression (LASSO, elastic net, and ridge regression) and polygenic score models to allow for a diversity of possible genetic architectures. The average predictive correlation from four-fold cross-validation was used to identify the best-performing model for each metabolite. The metabolite prediction models were then used to impute and test the associations of the CSF metabolites with 27 brain-related phenotypes from available GWAS summary statistics using the BADGERS approach¹⁴.

Results

A total of 606 significant SNP-CSF metabolite associations from 10 independent loci were identified in the discovery phase GWAS ($p < 1.48 \times 10^{-10}$, using the genome-wide significance threshold corrected for 338 tested metabolites), of which 488 SNPs (80.5%) and 8 loci (80%) were replicated ($p < 8.25 \times 10^{-5}$, adjusting for the 606 SNPs tested in replication). The GWAS meta-analysis identified a total of 1,183 significant SNPs across 16 metabolites ($p < 1.48 \times 10^{-10}$), with one distinct genetic locus of association per metabolite (Figure 1A; Supplementary Figures 1-16; Supplementary Tables 3-4). The genomic control inflation factor across all metabolite GWAS was 1.01, indicating little evidence of inflation (Figure 1B; Supplementary Figure 17). The SNP effect sizes and directions were consistent across the cohorts for the top SNP at each significant locus (Figure 1C).




Figure 1. GWAS meta-analysis of the CSF metabolome. A) Manhattan plot of the meta-analysis across all 338 metabolites tested, with the significant SNPs colored by the metabolic pathway of the associated metabolite. Age at CSF sample, sex, genotyping batch (WADRC only), and the first 5 principal components were controlled for in each individual GWAS. The top SNP of each locus is labeled with the nearest gene. The horizontal lines represent the genome-wide (5×10^{-8} , black) and Bonferroni-corrected significance thresholds (1.48×10^{-10} , red). Data points with $p < 1 \times 10^{-50}$ for N6-methyllysine are not shown. B) Q-Q plot based on the meta-analysis across all metabolites. C) Forest plot of the top SNPs from each significant locus across the discovery, replication, and meta-analysis ordered

by chromosome and BP position. The blue point represents the discovery GWAS, green the replication GWAS, and red the meta-analysis. The effect size refers to the GWAS beta effect estimate.

Of these 16 SNP-metabolite associations, 10 (guanosine, ethylmalonate, 3-ureidopropionate, N-acetylhistidine, tryptophan betaine, N-acetyl-beta-alanine, N-delta-acetylornithine, bilirubin, 2'-O-methylcytidine, and methionine sulfone) have been previously identified in GWAS of blood, urine, or saliva samples¹⁵⁻²⁰. Non-CSF regional association plots manually generated from publicly available summary statistics from Shin et al 2014¹⁶ and Long et al 2017¹⁷ were similar to corresponding CSF regional association plots, although the lead SNPs varied (Supplementary Figures 18-24). The remaining 6 associations were novel, either due to the metabolite not having been analyzed in a GWAS previously (N-acetylglutamate, 2-hydroxyadipate, 1-ribosyl-imidazoleacetate, and N6-methyllysine) or having been analyzed previously but without identifying the same locus found here in CSF (oxalate and betaine). The top SNP, nearest gene, and brain tissue expression quantitative trait locus (eQTL) effects from each of these genotype-metabolite associations are summarized in Supplementary Table 3 (meta-analysis results, eQTL information across tissue types, and GWAS Catalog associations for all 1,183 significant SNPs are in Supplementary Tables 4-6). In 9 out of the 16 loci, the eQTL effects of the top SNPs included the gene physically closest to the SNP itself.

The metabolite prediction models trained on the combined WADRC/WRAP data set showed varying abilities to predict each metabolite (Figure 2, Supplementary Figure 25, and Supplementary Tables 7-8). Among the top 10 best-predicted metabolites from genetics, 7 had a significant locus of association from the GWAS meta-analysis, and the top 6 were sparse models resulting from elastic net.




Figure 2. Metabolite prediction model performance. The prediction performance of the best model for each metabolite is shown arranged in order of decreasing R^2 . Metabolites with a significant locus from the GWAS meta-analysis are denoted with an asterisk.

Among the best-performing models for each metabolite, the R^2 between the predicted and actual metabolite levels ranged from 0.00083 to 0.29 (mean = 0.024, SD = 0.025), with 282 (83.4%) of the metabolites having a positive correlation and an $R^2 > 0.01$. Generally, models tended to contain 100 SNPs or more. The elastic net model was chosen as the best model type for 44.3% of the metabolites, followed by polygenic score models (28.4%), ridge regression (22.8%), and LASSO (4.5%).

There were 106 models with a positive correlation and a more conservative predictive $R^2 > 0.025$. These metabolite models were then tested for association with each of 27 neurological and psychiatric phenotypes (Supplementary Table 9)²¹⁻⁴². We report 19 metabolite-phenotype associations that were identified at a false discovery rate (FDR) cutoff of 0.05 (Table 1, Supplementary Table 10, Supplementary Figure 26). The phenotypes (and significantly associated metabolites) were schizophrenia³² (N-delta-acetylornithine, alpha-tocopherol, ethylmalonate, N6-methyllysine, guanosine, malate, unknown metabolite X-24699, 2-hydroxy-3-methylvalerate), cognitive performance³⁵ (N-delta-acetylornithine, glutaroylcarnitine [C5], benzoate), alcoholic drinks per week³⁸ (N-delta-acetylornithine, glycerol, cysteinylglycine), smoking behavior³⁸ (ethylmalonate), sleep duration³⁴ (cysteinylglycine disulfide), post-traumatic stress disorder

(PTSD)³¹ (unknown metabolite X-24295), and attention deficit hyperactivity disorder (ADHD)²⁴ (orotate and malate).

Table 1. Significant CSF metabolite-phenotype associations from BADGERS

Metabolite	Phenotype	Z score	P	Q value
ethylmalonate	Schizophrenia	4.14	3.46E-05	1.22E-03
	Smoking initiation	4.22	2.49E-05	2.64E-03
cysteinylglycine	Alcoholism (drinks per week)	3.24	1.20E-03	4.22E-02
2-hydroxy-3-methylvalerate	Schizophrenia	-3.16	1.58E-03	2.09E-02
	Alcoholism (drinks per week)	-4.49	7.05E-06	7.47E-04
N-delta-acetylornithine	Cognitive performance	4.83	1.34E-06	1.42E-04
	Schizophrenia	-5.26	1.42E-07	1.50E-05
glutaroylcarnitine (C5)	Cognitive performance	-3.72	2.01E-04	1.06E-02
cysteinylglycine disulfide	Sleep duration	-3.94	8.10E-05	8.59E-03
N6-methyllysine	Schizophrenia	-3.76	1.73E-04	4.58E-03
alpha-tocopherol	Schizophrenia	4.34	1.39E-05	7.39E-04
malate	ADHD	3.51	4.49E-04	2.38E-02
	Schizophrenia	-3.21	1.31E-03	2.09E-02
glycerol	Alcoholism (drinks per week)	-3.29	9.99E-04	4.22E-02
orotate	ADHD	3.61	3.05E-04	2.38E-02
guanosine	Schizophrenia	3.47	5.24E-04	1.11E-02
X - 24295	PTSD	-3.7	2.12E-04	2.25E-02
X - 24699	Schizophrenia	-3.18	1.47E-03	2.09E-02
benzoate	Cognitive performance	3.23	1.22E-03	4.30E-02

A two-sample MR analysis was performed for the 19 significant metabolite-phenotype associations. Four effects were significant after multiple testing correction, and all four of these effects were in the same direction as predicted by BADGERS but of smaller magnitude: N-delta-acetylornithine, ethylmalonate, and N6-methyllysine with schizophrenia and N-delta-acetylornithine with cognitive performance (Supplementary Tables 11-12).

Discussion

The results of this study demonstrate the feasibility of MWAS to elucidate novel metabolite-phenotype associations using metabolite prediction models built from scarce sample types and GWAS summary statistics. The first major component of MWAS was to identify SNP-metabolite associations. We identified 16 genotype-metabolite associations. As no previous metabolome-wide GWAS in the CSF had been reported to our knowledge, we assessed the validity and novelty of the results by comparing identified loci with previous GWAS of metabolites in blood, urine, and saliva^{15-19,43-47}. Many of the loci discovered in this analysis of CSF metabolites replicate loci that have been previously discovered, indicating that some of the regulatory machinery of the metabolome is shared across biological compartments.

The 6 novel SNP-metabolite associations we identified appear to be biologically feasible based on previous research and are likely to be of general biomedical interest. The GWAS Catalog⁴⁸ reports 76 different phenotypes to be associated with these 6 loci (Supplementary Table 6). The chromosome 3 locus (rs17279437) associated with CSF betaine levels is closest to *SLC6A20*, a gene that has been implicated in betaine transport⁴⁹ and previously associated with N,N-dimethylglycine^{43,50}, which is related to betaine⁵¹. The SNPs associated with oxalate (ethanedioate) did not have any documented associations in the GWAS Catalog nor significant eQTLs in the Genotype-Tissue Expression project (GTEx)⁵². However, oxalate is a metabolite of the chemotherapeutic drug oxaliplatin⁵³, and the locus identified here is upstream of *EPHA6*, a gene that has been implicated in neuropathy from another chemotherapeutic drug, paclitaxel⁵⁴. The locus associated with 1-ribosyl-imidazoleacetate included brain eQTLs for several genes, including *NAPRT*, which encodes an enzyme (nicotinate phosphoribosyltransferase) involved in transferring ribosyl groups⁵⁵. The locus for N6-methyllysine includes brain eQTLs for the *PYROXD2* gene, which has been associated with other metabolites (trimethylamine and dimethylamine) in previous studies^{50,56,57}. The locus associated with N-acetylglutamate included a brain eQTL for the *SLC13A3* gene that encodes sodium-dependent dicarboxylate cotransporter 3, which has been implicated as a transporter for N-acetylglutamate and for N-carbamoylglutamate, a drug used to treat N-acetylglutamate synthase deficiency⁵⁸. The biology behind the locus for 2-hydroxyadipate was less immediately clear, but the locus includes eQTLs for the lincRNA gene *RP4-625H18.2*.

These GWAS results underscore the importance of studying scarce sample types like the CSF as they included a number of previously unreported genotype-metabolite associations. Two such metabolites (oxalate and betaine) have been previously studied in blood and urine samples, but different genetic loci were identified^{15–17,20,43,46,50}. For oxalate, the strongest SNP association from blood had a $p = 1.54 \times 10^{-8}$ (rs368292858, chromosome 12, base pair (BP) 109,713,327)¹⁷, while the strongest SNP association in CSF was stronger at $p = 5.64 \times 10^{-11}$ (rs35170539, chromosome 3, BP 96,314,015), despite having a smaller sample size. For betaine, the strongest SNP association was reported in blood at $p = 1.49 \times 10^{-19}$ (rs16876394, chromosome 5, BP 78,346,769)¹⁶, while in the CSF the top association was at $p = 4.73 \times 10^{-15}$ (rs17279437, chromosome 3, BP 45,814,094). These CSF findings potentially represent genetic loci of control that are unique to the CSF, as they have not been identified in non-CSF studies.

The metabolite prediction models achieved comparable performance to TWAS and imaging-wide association study (IWAS) applications. Average predictive R^2 values from TWAS have tended to range from 0.1 (in-sample)^{9,59} to 0.02–0.05 (out-of-sample)⁹. The average in-sample R^2 from our MWAS was lower (0.024), perhaps as a result of metabolites being less directly controlled by the genome than gene expression and the challenge of using the entire genome for prediction rather than just cis-SNPs. Nonetheless, 83.4% of the metabolites here could still be predicted at or above the R^2 threshold of 0.01 used by previous studies to filter out poorly predicted gene expression values or endophenotypes^{9,60}, supporting the feasibility of MWAS to perform comparably to TWAS and IWAS in studying disease associations.

One benefit of this study is the insight gained into the genetic architecture of scarce sample types. The CSF metabolites studied here showed a wide range of genetic architectures as seen through the model types best able to predict them. While some metabolites with significant loci from the GWAS favored sparse models, other metabolites tended to be best predicted by a polygenic model. The performance of these predictive models also hints at the relative importance of genetics for each metabolite, which is especially helpful for data sets that are too small for effective heritability estimation, as was the case here.

The MWAS analysis identified a number of plausible CSF metabolite-phenotype associations. Three of the metabolites predicted to be associated with schizophrenia—alpha-tocopherol, N-delta-acetylornithine, and N6-methyllysine—have been implicated by previous research. Alpha-tocopherol, also known as vitamin E, is an antioxidant whose level has been noted to change in the blood during acute and chronic phases of schizophrenia⁶¹. Levels of N-acetylornithine, an amino acid, has been shown to differ between case and control brains in mice treated with haloperidol, an antipsychotic medication used to treat schizophrenia⁶². Finally, L-lysine, a related compound to N6-methyllysine, has been investigated as a potential treatment for schizophrenia⁶³. Beyond schizophrenia, other putative metabolite-phenotype associations from this analysis appeared to be feasible as well: cysteinylglycine disulfide (associated with sleep duration) is a disulfide, and disulfides have been explored as a marker of stress in obstructive sleep apnea⁶⁴, and glutaroylcarnitine (associated with cognitive performance) levels are known to be altered in glutaric acidemia type 1, which can manifest in neurological problems like dystonia⁶⁵. Among the novel findings, N-delta-acetylornithine (associated with schizophrenia) was also associated with cognition and alcoholism. Though this particular metabolite does not appear to have been reported previously in association with cognitive performance and alcoholism, these two phenotypes have long been associated with schizophrenia^{66,67}.

An additional analysis made possible by the metabolite-phenotype association testing is elucidating the biology of unidentifiable metabolites. The metabolite X-24295 was significantly associated with PTSD, but little information was available on it. However, by examining the nominally significant genetic locus associated with the metabolite on chromosome 10 (BP 60,794,328-61,050,339), nearby genes and phenotypes associated with those genes were identified (genes included *PHYHIPL*, *TRAF6P1*, *LINC00844*, and *FAMI3C*; phenotypes included DNA methylation, sleep duration, and QT-interval duration in *Trypanosoma cruzi* seropositivity). Together, these findings support and potentially shed light on the biological mechanism for metabolite X-24295's association with PTSD, as PTSD has been shown to be related to traumatic brain injury⁶⁸ (which has been associated with *PHYHIPL* in mice⁶⁹), altered DNA methylation⁷⁰, and sleep disturbances⁷¹. These genetic annotations may also aid in the identification of the metabolite itself, as has been demonstrated by other metabolome-wide GWAS analyses¹⁷.

The identification of promising drug targets is a major goal of metabolomics, and studies in insulin pathways^{72,73}, obesity⁷⁴, type 2 diabetes⁷⁵, and atherosclerosis⁷⁶ have shown the feasibility of identifying metabolites that affect disease in follow-up experimentation. In a recent review, a drug development pipeline was proposed for metabolomics-identified targets, beginning with two rounds of case-control studies with 50 or more participants⁷⁷. Multiple studies on such a large scale

may be logistically difficult to arrange for many diseases, which is where MWAS can play a key role. MWAS offers a potential alternative for the initial discovery of targets that avoids the need for direct metabolite quantification, instead imputing metabolites using more readily available genetic information.

One limitation of this study was the small sample size available for running the GWAS and training the metabolite prediction models. Having only a few hundred samples likely precluded the identification of some genetic loci associated with CSF metabolites; as such, the resulting predictive models could potentially be improved. However, even at the current sample size, the majority of metabolites could be predicted from genetics at the threshold of typical TWAS applications, and those studies have been successful in identifying gene-phenotype associations as noted earlier. One possible explanation for the success of this GWAS in spite of the smaller sample size is that molecular traits like metabolites are more biologically proximal to the DNA and thus may be more likely to be strongly affected by genetic variants compared to complex disease. Another limitation is that only individuals of European ancestry were studied, which may limit the generalizability of these findings to individuals of non-European ancestry. Future applications of MWAS in diverse populations will be needed to ensure that disease associations can be identified for a broader range of populations. Finally, the metabolite-phenotype associations identified here may not necessarily be causal. Even with the results of the two-sample MR providing significant, consistent support for some of the metabolite-phenotype associations, more needs to be known about the functional roles of these metabolites and their related genetic loci to adequately assess the assumptions of an MR analysis. Nevertheless, MWAS provides a powerful tool for the initial discovery of metabolite-phenotype associations that can then be followed up experimentally.

Conclusion

Here, we conducted the first metabolome-wide GWAS of the CSF metabolome, identifying 16 genome-wide significant associations. Some of these loci appear to be unique to the CSF based on what is currently known about the blood, urine, and saliva metabolomes. Using these genetic associations, we built genome-wide prediction models for the metabolites, achieving predictions that are comparable to those currently used by TWAS applications. We leveraged these genetic associations to conduct a summary-statistic-based MWAS on a diversity of neurological and psychiatric phenotypes, identifying 19 significant associations, some supported by previous literature and others novel. These findings collectively provide insight into the genetic architecture of the CSF metabolome and the roles of CSF metabolites in disease, demonstrating the potential of this framework to make inroads into the omics of scarce sample types.

Acknowledgments

We thank Stephen Ortmann for his help with manuscript preparation and Diandra Denier for providing additional information about some of the metabolites in this study.

We would like to thank WRAP and WADRC participants and the Wisconsin Alzheimer's Institute (WAI) and WADRC staff for their contributions to the WRAP and WADRC studies. Without their efforts this research would not be possible. This research is supported by National Institutes of Health (NIH) grants R01AG27161 (Wisconsin Registry for Alzheimer Prevention: Biomarkers of Preclinical AD) R01AG054047 (Genomic and Metabolomic Data Integration in a Longitudinal Cohort at Risk for Alzheimer's Disease), and P30AG062715 (Wisconsin Alzheimer's Disease Research Center Grant), the Helen Bader Foundation, Northwestern Mutual Foundation, Extendicare Foundation, State of Wisconsin, the Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS) grant UL1TR000427, and the University of Wisconsin-Madison Office of the Vice Chancellor for Research and Graduate Education with funding from the Wisconsin Alumni Research Foundation. This research was supported in part by the Intramural Research Program of the National Institute on Aging. Computational resources were supported by a core grant to the Center for Demography and Ecology at the University of Wisconsin-Madison (P2CHD047873). Author DJP was supported by an NLM training grant to the Bio-Data Science Training Program (T32LM012413). Author BFD was supported by an NLM training grant to the Computation and Informatics in Biology and Medicine Training Program (NLM 5T15LM007359). Author YKD was supported by a training grant from the National Institute on Aging (T32AG000213). Author HK was supported by National Science Foundation (NSF) grant DMS-1811414 (Theory and Methods for Inferring Causal Effects with Mendelian Randomization).

We thank the University of Wisconsin Madison Biotechnology Center Gene Expression Center for providing Illumina Infinium genotyping services.

The GTEx Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from the GTEx Portal on 8/1/19.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Data and code availability

The datasets generated and analyzed during the current study may be requested from the WADRC at <https://www.adrc.wisc.edu/apply-resources>. Full GWAS meta-analysis summary statistics may be accessed at ftp://ftp.biostat.wisc.edu/pub/lu_group/Projects/MWAS/.

Author contributions

Authors DJP, CDE, and QL conceived and designed the study. DJP conducted the analyses and wrote the manuscript. BFD and YKD cleaned the genetic data from the WRAP and WADRC cohort studies, respectively. KMK assisted with the metabolite prediction model building. XZ and YW assisted with the implementation of BADGERS and the preparation of the AD GWAS data.

HK assisted with the interpretation of the MR analysis. CMM, SCJ, and SA oversaw the WADRC and WRAP cohort studies. All authors contributed to the revision of the manuscript.

Competing interests declaration

Author SCJ served as a consultant to Roche Diagnostics in 2018. Other authors have no competing interests to declare.

Additional information

Correspondence and requests for materials should be addressed to Qiongshi Lu.

The following supplementary information is available for this paper:

Supplementary Table 1: Study cohort description

Supplementary Table 2: Metabolite information

Supplementary Table 3: Top significant SNP-metabolite associations

Supplementary Table 4: GWAS meta-analysis significant SNPs

Supplementary Table 5: GWAS meta-analysis significant eQTLs

Supplementary Table 6: GWAS Catalog results for significant SNPs

Supplementary Table 7: Metabolite predictive model summary

Supplementary Table 8: Metabolite predictive model SNP coefficients

Supplementary Table 9: Neurological and psychiatric GWAS used in BADGERS

Supplementary Table 10: BADGERS association results

Supplementary Table 11: MR analysis results

Supplementary Table 12: Neurological and psychiatric GWAS used in the MR analysis

Supplementary Figure 1: GWAS meta-analysis results for methionine sulfone (X44748)

Supplementary Figure 2: GWAS meta-analysis results for N-delta-acetylmethionine (X43249)

Supplementary Figure 3: GWAS meta-analysis results for bilirubin (X43807)

Supplementary Figure 4: GWAS meta-analysis results for betaine (X3141)

Supplementary Figure 5: GWAS meta-analysis results for oxalate (ethanedioate) (X20694)

Supplementary Figure 6: GWAS meta-analysis results for tryptophan betaine (X37097)

Supplementary Figure 7: GWAS meta-analysis results for 2-hydroxyadipate (X31934)

Supplementary Figure 8: GWAS meta-analysis results for N-acetylhistidine (X33946)

Supplementary Figure 9: GWAS meta-analysis results for 3-ureidopropionate (X3155)

Supplementary Figure 10: GWAS meta-analysis results for 1-ribosyl-imidazoleacetate (X61868)

Supplementary Figure 11: GWAS meta-analysis results for 2'-O-methylcytidine (X57554)

Supplementary Figure 12: GWAS meta-analysis results for N-acetyl-beta-alanine (X37432)

Supplementary Figure 13: GWAS meta-analysis results for N6-methyllysine (X62249)

Supplementary Figure 14: GWAS meta-analysis results for ethylmalonate (X15765)

Supplementary Figure 15: GWAS meta-analysis results for guanosine (X1573)

Supplementary Figure 16: GWAS meta-analysis results for N-acetylglutamate (X15720)

Supplementary Figure 17: Genomic inflation factor distribution

Supplementary Figure 18: Side-by-side regional association plots for methionine sulfone (X44878)

Supplementary Figure 19: Side-by-side regional association plots for N-delta-acetylornithine (X43249)

Supplementary Figure 20: Side-by-side regional association plots for bilirubin (X43807)

Supplementary Figure 21: Side-by-side regional association plots for tryptophan betaine (X37097)

Supplementary Figure 22: Side-by-side regional association plots for N-acetylhistidine (X33946)

Supplementary Figure 23: Side-by-side regional association plots for N-acetyl-beta-alanine (X37432)

Supplementary Figure 24: Side-by-side regional association plots for ethylmalonate (X15765)

Supplementary Figure 25: Metabolite prediction model performance by model type

Supplementary Figure 26: Metabolite-phenotype association analysis Q-Q plot

Online Methods

Study participants

The metabolomics data used in this study came from CSF samples analyzed in the WADRC and WRAP cohort studies. The WADRC, previously described⁷⁸, is a longitudinal cohort study of memory, aging, and AD in middle and older aged adults who were recruited into one of six subgroups: 1) mild late-onset AD; 2) mild cognitive impairment (MCI); 3) age-matched healthy older controls (age > 65); 4) middle-aged adults with a positive parental history of AD; 5) middle-aged adults with a negative parental history of AD; and 6) middle-aged adults with indeterminate parental history of AD. The National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)⁷⁹ and National Institute on Aging and Alzheimer's Association (NIA-AA)⁸⁰ criteria were used for clinical diagnoses. Briefly, the inclusion criteria for WADRC participants included an age \geq 45, decisional capacity, and the ability to fast from food and drink for 12 hours. Briefly, exclusion criteria included history of certain medical conditions (e.g., kidney dysfunction, congestive heart failure, major neurologic disorders other than dementia, and others), lack of a study partner, and contraindication to biomarker procedures.

The WRAP study, also previously described¹², is a longitudinal cohort study of AD in middle and older aged adults who are cognitively healthy at baseline, enriched for persons with a parental history of AD. Briefly, inclusion criteria include being between the ages of 40 and 65, fluent in English, able to complete neuropsychological testing, and free of health conditions that might preclude study participation. Briefly, exclusion criteria included having a diagnosis or evidence of dementia at baseline.

This study was performed as part of the Generations of WRAP (GROW) study, which was approved by the University of Wisconsin Health Sciences Institutional Review Board. Participants in the WADRC and WRAP studies provided written informed consent.

CSF samples

A subset of participants in both the WADRC and WRAP studies had LPs conducted to collect CSF. Similar collection protocols and staff were used in both studies to collect and store the CSF samples, which have been previously described^{12,81}. Briefly, fasting CSF samples were drawn from study participants in the morning through LP and then mixed, centrifuged, aliquoted, and stored at -80 degrees Celsius.

Samples were kept frozen until they were shipped overnight to Metabolon, Inc. (Durham, NC), which similarly kept samples frozen at -80 degrees Celsius until analysis. Metabolon used Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) to conduct an untargeted metabolomics analysis of the CSF samples, processing both WADRC and WRAP simultaneously on the same platform. A total of 412 metabolites were quantified, of which

354 were identified and 58 were of unknown structural identity. The relative peak intensity was quantified for each metabolite in each sample using area-under-the-curve. Metabolite values were divided by the median of all values for that metabolite. Quantified metabolites were annotated with metabolite identifiers, chemical properties, and pathway information.

A total of 689 participants (532 from WADRC and 168 from WRAP) with CSF samples analyzed for metabolites were initially included before metabolite quality control.

Initial metabolite processing

Initial metabolite quality control was performed on the 689 CSF samples, including assessment of missingness and variation, imputation, and transformation. First, the missingness of each metabolite across samples was calculated. A metabolite value may be missing for several reasons: the metabolite was not present in the sample; the metabolite was present at a level below the detection limit for that metabolite; or the metabolite was present, but there was a sample or technical issue that precluded its detection by MS. Non-xenobiotic metabolites were removed if they were missing for $\geq 30\%$ of samples. Xenobiotic metabolites, which may reasonably be completely absent in samples, were removed if they were missing for $\geq 80\%$ of samples. CSF samples were removed from analysis if any sample was missing measurements for $\geq 40\%$ of all metabolites in the data set. Metabolites with an interquartile range of 0 were removed because of the limited variation available for statistical analysis. At the end of these initial processing steps, 378 metabolites across 672 samples remained.

Imputation was then performed for each cohort's samples separately. Non-xenobiotics were imputed to half the minimum value within each cohort, while xenobiotics were not imputed since they could feasibly be absent from the CSF. Due to consistent right-skew in the data, each metabolite was \log_{10} transformed.

Initial genotype processing

In the WADRC cohort, samples were sent to the National Alzheimer's Coordinating Center (NACC) and genotyped by the Alzheimer's Disease Genetics Consortium (ADGC) using the Illumina HumanOmniExpress-12v1_A, Infinium HumanOmniExpressExome-8 v1-2a, or Infinium Global Screening Array v1-0 (GSAMD-24v1-0_20011747_A1) BeadChip. All genetic data underwent stringent quality control prior to imputation and analysis: variants or samples with $> 2\%$ missingness, variants out of Hardy-Weinberg equilibrium (HWE) ($p < 1 \times 10^{-6}$), or samples with inconsistent genetic and self-reported sex data were removed. After pre-imputation processing with the Haplotype Reference Consortium (HRC) Checking tool⁸², the genotypes were uploaded to the Michigan Imputation Server⁸³ where they were phased using Eagle2⁸⁴ and imputed to the HRC reference panel⁸⁵. Variants with a low quality score ($R^2 < 0.8$) or out of HWE were removed. Quality control was carried out separately for each genotyping chip's data. After imputation, the various chip data sets were merged together.

In the WRAP cohort, DNA was extracted from whole blood samples and genotyped using the Illumina Multi-Ethnic Genotyping Array at the University of Wisconsin Biotechnology Center¹³. Briefly, samples and variants with high missingness (> 5%) and samples with inconsistent genetic and self-reported sex were removed. 1,198 samples from individuals of European descent with 898,220 variants were then imputed using the Michigan Imputation Server and the HRC reference panel. Variants with a low imputation quality score ($R^2 < 0.8$), with a low minor allele frequency (MAF) (< 0.001), or out of HWE were removed. Variants were annotated based on the GRCh37 assembly.

Data cleaning

For this study, the initial sample contained those samples with both genetic and metabolomic data (440 samples from WADRC; 165 samples from WRAP). Samples were then removed for missing age at LP, a cognitive diagnosis date more than two years from the LP date, non-European ancestry (due to lack of sample size in other ancestry groups), or having withdrawn from or being ineligible for the study. In order to maximize the generalizability of the genetic-metabolite associations, only participants who were cognitively normal at the time of the CSF draw were kept. When multiple CSF draws were available from a participant, only the first qualifying sample was retained. Similarly, if participants were related (according to identity by descent in ADRC or self-reported family relationships in WRAP), only one participant was kept per related group in order to remove genetic correlation between participants.

Metabolite missingness was then reassessed among the cleaned data set to ensure sufficient sample size for estimating SNP effects in the GWAS: any metabolite missing $\geq 50\%$ across a cohort's samples was removed. To address potential population stratification, principal component analysis (PCA) was conducted within each cohort on the subset of participants to be analyzed in the GWAS. The number of principal components (PCs) controlled for in the GWAS was selected based on a visual inspection of the scree plots, which in both cases was 5 PCs. Finally, SNPs missing $\geq 1\%$ across the remaining samples in a cohort were removed, leaving 7,049,691 SNPs in WADRC and 10,494,131 SNPs in WRAP. A total of 338 metabolites across 155 samples in WADRC and 136 samples in WRAP remained after these quality control procedures.

GWAS

A GWAS was performed for each metabolite in each cohort using PLINK⁸⁶ (version 1.90b6.3). Linear regression with an additive genetic model was used, controlling for age at CSF draw, sex, the first 5 PCs, and the NACC genotyping round (for WADRC only). Post-GWAS, SNPs were removed with a $MAF \leq 0.05$. A Q-Q plot and Manhattan plot were generated for each GWAS using the R package qqman⁸⁷ (version 0.1.4). The genomic inflation factor was calculated for each metabolite in each cohort using the median χ^2 statistic.

In the discovery phase GWAS (WADRC cohort), a genome-wide significance threshold (5×10^{-8}) with a Bonferroni correction for the number of metabolites tested (338) resulted in a significance

threshold of 1.48×10^{-10} . The significant SNPs from the discovery phase were identified and then compared to the replication phase (WRAP cohort) to assess replication at a significance threshold of 0.05 with a Bonferroni correction for the number of significant SNPs tested from the discovery phase (606), for a final significance threshold of replication of 8.25×10^{-5} .

The discovery and replication phase GWAS results were then meta-analyzed using the inverse-variance-weighted approach implemented in METAL⁸⁸ (2018-08-28 version, STDERR scheme). Only SNPs present in both the discovery and replication GWAS were retained, and a genome-wide significance threshold Bonferroni-corrected for the number of metabolites analyzed ($p = 1.48 \times 10^{-10}$) was used for reporting associations. Q-Q plots, Manhattan plots, and genomic inflation factors were calculated for the meta-analysis as before, and LocusZoom⁸⁹ (version 1.4) was used to generate regional genetic association plots for a 1 Mb region around the top SNP at each significant locus, using the 1000 Genomes Nov2014 EUR population for linkage disequilibrium (LD) estimation (Supplementary Figures 1-16).

Evaluation of significant loci

The significant SNPs from the meta-analysis GWAS were evaluated for the feasibility of a connection with their associated metabolites. Each SNP was annotated with the nearest gene using GENCODE⁹⁰ annotations (version 19) and known eQTLs in CNS-related tissues using GTEx⁵² (version 7) (Supplementary Table 5). Regions around the significant SNPs were also looked up in the GWAS Catalog for previously reported phenotype associations using the R package gwasrapidd⁹¹ (version 0.99.8) (Supplementary Table 6). Additionally, each significant SNP-metabolite association was checked against previously published GWAS of metabolites^{15-19,44,45,47} in non-CSF fluids or tissues, with a focus on publications that also used Metabolon for metabolite quantification and thus were more likely to have measured the same metabolites that were measured here. To match metabolites by name across data sets when Metabolon identifiers were not available, string-matching functions from MetaboAnalystR⁹² (version 1.0.2) and stringdist⁹³ (version 0.9.5.5) were used to match metabolite names, which were then manually reviewed for accuracy. Each SNP-metabolite association was examined in the results of each of the non-CSF studies for the presence of the metabolite and whether the SNP association was replicated. For studies with publicly available GWAS summary statistics, LocusZoom plots were created of the CSF-significant genetic regions using the publicly available non-CSF summary statistics data to allow for side-by-side comparison of the CSF associations and the non-CSF associations for the same metabolite at the same locus (Supplementary Figures 18-24).

Metabolite prediction models

Metabolite prediction models were built and selected using four-fold cross-validation. To maximize the sample size available for training metabolite prediction models, a combined WADRC and WRAP data set was created. Only SNPs present in both data sets, present for all individuals, and with a $MAF \geq 0.05$ were retained. To account for differences in SNP annotations,

SNPs were harmonized across WADRC, WRAP, and the 1000 Genomes Phase 3 CEU samples that were used as an LD reference such that all SNPs were oriented to the same strand and major/minor allele annotation. SNPs that were inconsistent across the data sets or ambiguous SNPs were removed. The combined WADRC/WRAP data set was then partitioned evenly into four portions, with a training fold comprising three portions merged together and a testing fold comprising the remaining portion.

Within each training fold of data, PLINK was used to run a GWAS of each metabolite using a linear, additive model, controlling for age at CSF collection, sex, the top 5 PCs (calculated in the combined data set), and an indicator for WADRC or WRAP genotyping round. Variance inflation factors were restricted to being less than 50 (four metabolites were excluded from further analysis due to a high inflation factor in at least one fold). The resulting fold-specific GWAS files were then clumped down to independent SNPs ($r^2 < 0.1$ within a 1000 kb window using the 1000 Genomes CEU reference panel for LD estimation) with a p-value threshold of 0.01 using PLINK.

Metabolite prediction models were built for each metabolite within each fold of training data. Four general model types covering a range of genetic architecture assumptions were employed: LASSO⁹⁴, elastic net⁹⁵, ridge regression⁹⁶, and polygenic score models⁹⁷. The 3 penalized regression models (LASSO, elastic net, and ridge regression) were implemented using the R package glmnet⁹⁸ (version 2.0-18). An 11x11 grid of parameter combinations (lambda and alpha) was created. Lambdas ranged from 1.0×10^{-5} to 1.0 (10 raised to exponents incremented by 0.5); alphas ranged from 0.0 to 1.0 (incremented by 0.1). Models were classified based on the alpha value (1.0 = LASSO, 0.0 = ridge regression, others = elastic net). Model predictors included all clumped SNPs and the same covariates used for the fold-specific GWAS, but the regularization penalty was only applied to the SNPs. The polygenic score models were implemented using PRSice⁹⁹ (version 2.2.4). Three p-value thresholds were used: 0.0001, 0.001, and 0.01.

Each fold-specific metabolite prediction model was tested on the corresponding testing fold to determine the correlation and R^2 between the predicted and actual metabolite values. The mean predictive correlation was taken across all folds for each model, with the highest-correlated model chosen as the best predictive model for that metabolite. For each metabolite, the type of model, mean number of SNPs used, and presence of significant meta-analysis GWAS loci were recorded (Supplementary Table 7).

Metabolite-phenotype association testing

To test the association between imputed metabolites and the various brain-related phenotypes, two components were needed: metabolite prediction model SNP weights and brain-related GWAS summary statistics. The best prediction models per metabolite chosen by the four-fold cross-validation described above were initially considered for the association testing. Only metabolite prediction models with a positive correlation and a mean predictive $R^2 > 0.025$ were retained. The model type and parameter settings for each metabolite's best-performing model were then run on the entire WADRC/WRAP combined sample to generate the final model weights for all SNPs included in the model (Supplementary Table 8).

The phenotypes for the association analysis were chosen based on the feasibility of the CSF metabolome being relevant to the phenotype and the availability of GWAS summary statistics for the phenotype. The only exception was the GWAS for the AD proxy phenotype, which was developed in-house on the UK Biobank data set as a surrogate measure for AD risk based on parental diagnosis and age at diagnosis, following previous research^{100,101}. The CNS phenotypes and sources of the GWAS summary statistics²¹⁻⁴² are listed in Supplementary Table 9. All GWAS summary statistics files were harmonized to the GRCh37 SNP annotations and orientations of the WADRC/WRAP combined data set used for model training. For GWAS summary statistics with only odds ratios or Z-scores reported, beta effect sizes were converted or estimated from the data provided. To maximize the SNP overlap between the model training SNPs and the GWAS summary statistics, the ImpG method¹⁰² (FIZI package, version 0.6; Python, version 3.8) was used to impute missing SNP effect sizes in the GWAS summary statistics. Only SNPs that matched between the training data and the imputed GWAS summary statistics were retained.

The BADGERS (Biobank-wide Association Discovery using GENetic Risk Scores) software package¹⁴ was used to test the association of each imputed CSF metabolite with each of the GWAS summary statistics phenotypes (Supplementary Table 10). A Q-Q plot of all BADGERS association test results was created to assess potential inflation (Supplementary Figure 26). An FDR was calculated using the qvalue¹⁰³ (version 2.18.0) package for each GWAS phenotype at a threshold of 0.05 to report significant associations. A Bonferroni-corrected significance threshold based on the number of metabolite (106) and phenotype (27) combinations tested with BADGERS ($p = 0.05 / 2862 = 1.7 \times 10^{-5}$) was additionally used to report the most conservative associations. A manual search of published literature was conducted to check for the biological feasibility of the metabolite-phenotype associations estimated by BADGERS. For metabolites marked as unknown by Metabolon, the region around the top genetic loci for the metabolite from the GWAS meta-analysis was looked up in the GWAS Catalog to identify any other associations that might inform the metabolite's role or identity.

A two-sample Mendelian Randomization was performed for each of the significant metabolite-phenotype associations from BADGERS, using the meta-analysis GWAS results for the metabolites described above and a phenotype GWAS from the IEU GWAS Database (Supplementary Table 11). When possible, the same phenotype GWAS that was used in BADGERS was used for the MR analysis; otherwise, a similar phenotype from a different study was used (Supplementary Table 12). The MR analysis was conducted using the TwoSampleMR¹⁰⁴ (version 0.5.0) package, using the Wald ratio (“mr_wald_ratio”), inverse-variance-weighted (“mr_ivw”), Egger regression (“mr_egger_regression”), and weighted median (“mr_weighted_median”) methods. A Bonferroni-corrected significance threshold for the number of MR analyses performed (42) was used for reporting significant results ($p = 0.05 / 42 = 1.2 \times 10^{-3}$).

General bioinformatic tools

General data analysis was performed primarily using R¹⁰⁵ (versions 3.6.0 and 3.6.1), RStudio¹⁰⁶ (version 1.2.1335), and the Tidyverse suite of R packages¹⁰⁷.

References

1. Suhre, K. *et al.* Metabolic Footprint of Diabetes: A Multiplatform Metabolomics Study in an Epidemiological Setting. *PLOS ONE* **5**, e13953 (2010).
2. Oberbach, A. *et al.* Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes. *J. Proteome Res.* **10**, 4769–4788 (2011).
3. Sreekumar, A. *et al.* Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature* **457**, 910–914 (2009).
4. Trushina, E., Dutta, T., Persson, X.-M. T., Mielke, M. M. & Petersen, R. C. Identification of Altered Metabolic Pathways in Plasma and CSF in Mild Cognitive Impairment and Alzheimer’s Disease Using Metabolomics. *PLOS ONE* **8**, e63644 (2013).
5. Schwarz, E. & Bahn, S. Biomarker discovery in psychiatric disorders. *ELECTROPHORESIS* **29**, 2884–2890 (2008).
6. Simrén, J., Ashton, N. J., Blennow, K. & Zetterberg, H. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. *Curr Opin Neurobiol* **61**, 29–39 (2019).
7. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nat Rev Neurol* **6**, 131–144 (2010).
8. Wainberg, M. *et al.* Opportunities and challenges for transcriptome-wide association studies. *Nat Genet* **51**, 592–599 (2019).
9. Gamazon, E. R. *et al.* A gene-based association method for mapping traits using reference transcriptome data. *Nat Genet* **47**, 1091–1098 (2015).
10. Gusev, A. *et al.* Transcriptome-wide association study of schizophrenia and chromatin activity yields mechanistic disease insights. *Nat Genet* **50**, 538–548 (2018).

11. Hu, Y. *et al.* A statistical framework for cross-tissue transcriptome-wide association analysis. *Nat Genet* **51**, 568–576 (2019).
12. Johnson, S. C. *et al.* The Wisconsin Registry for Alzheimer’s Prevention: A review of findings and current directions. *Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring* **10**, 130–142 (2018).
13. Darst, B. F., Lu, Q., Johnson, S. C. & Engelman, C. D. Integrated analysis of genomics, longitudinal metabolomics, and Alzheimer’s risk factors among 1,111 cohort participants. *Genet Epidemiol* **43**, 657–674 (2019).
14. Yan, D. *et al.* Biobank-wide association scan identifies risk factors for late-onset Alzheimer’s disease and endophenotypes. *bioRxiv* 468306 (2018) doi:10.1101/468306.
15. Suhre, K. *et al.* Human metabolic individuality in biomedical and pharmaceutical research. *Nature* **477**, (2011).
16. Shin, S.-Y. *et al.* An atlas of genetic influences on human blood metabolites. *Nat Genet* **46**, 543–550 (2014).
17. Long, T. *et al.* Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. *Nat Genet* **49**, 568–578 (2017).
18. Yousri, N. A. *et al.* Whole-exome sequencing identifies common and rare variant metabolic QTLs in a Middle Eastern population. *Nat Commun* **9**, 333 (2018).
19. Nag, A. *et al.* Genome-wide scan identifies novel genetic loci regulating salivary metabolite levels. *bioRxiv* 687350 (2019) doi:10.1101/687350.
20. Schlosser, P. *et al.* Genetic studies of urinary metabolites illuminate mechanisms of detoxification and excretion in humans. *Nat Genet* 1–10 (2020) doi:10.1038/s41588-019-0567-8.
21. Benyamin, B. *et al.* Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosis. *Nat Commun* **8**, (2017).

22. Watson, H. J. *et al.* Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nat Genet* **51**, 1207–1214 (2019).
23. Meier, S. M. *et al.* Genetic Variants Associated With Anxiety and Stress-Related Disorders: A Genome-Wide Association Study and Mouse-Model Study. *JAMA Psychiat* (2019) doi:10.1001/jamapsychiatry.2019.1119.
24. Demontis, D. *et al.* Discovery of the first genome-wide significant risk loci for attention-deficit/hyperactivity disorder. *Nat Genet* **51**, 63–75 (2019).
25. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet* **51**, 431–444 (2019).
26. Stahl, E. A. *et al.* Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nat Genet* **51**, 793–803 (2019).
27. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. *Lancet Neurol* **13**, 893–903 (2014).
28. Wray, N. R. *et al.* Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet* **50**, 668–681 (2018).
29. Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Mol Psychiatry* **23**, 1181–1188 (2018).
30. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. *Lancet Neurol* **18**, 1091–1102 (2019).
31. Nievergelt, C. M. *et al.* International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. *Nat Commun* **10**, 4558 (2019).
32. Pardiñas, A. F. *et al.* Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat Genet* **50**, 381–389 (2018).

33. Yu, D. *et al.* Interrogating the Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. *Am J Psychiat* **176**, 217–227 (2019).
34. Jones, S. E. *et al.* Genome-Wide Association Analyses in 128,266 Individuals Identifies New Morningness and Sleep Duration Loci. *PLoS Genet* **12**, (2016).
35. Lee, J. J. *et al.* Gene discovery and polygenic prediction from a 1.1-million-person GWAS of educational attainment. *Nat Genet* **50**, 1112–1121 (2018).
36. Day, F. R., Ong, K. K. & Perry, J. R. B. Elucidating the genetic basis of social interaction and isolation. *Nat Commun* **9**, (2018).
37. Okbay, A. *et al.* Genetic variants associated with subjective well-being, depressive symptoms and neuroticism identified through genome-wide analyses. *Nat Genet* **48**, 624–633 (2016).
38. Liu, M. *et al.* Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet* **51**, 237–244 (2019).
39. Demontis, D. *et al.* Genome-wide association study implicates CHRNA2 in cannabis use disorder. *Nat Neurosci* **22**, 1066–1074 (2019).
40. Erlangsen, A. *et al.* Genetics of suicide attempts in individuals with and without mental disorders: a population-based genome-wide association study. *Mol Psychiatry* 1–12 (2018) doi:10.1038/s41380-018-0218-y.
41. Adams, H. H. *et al.* Novel genetic loci underlying human intracranial volume identified through genome-wide association. *Nat Neurosci* **19**, 1569–1582 (2016).
42. Hibar, D. P. *et al.* Novel genetic loci associated with hippocampal volume. *Nat Commun* **8**, (2017).
43. Suhre, K. *et al.* A genome-wide association study of metabolic traits in human urine. *Nat Genet* **43**, 565–569 (2011).

44. Kettunen, J. *et al.* Genome-wide association study identifies multiple loci influencing human serum metabolite levels. *Nat Genet* **44**, 269–276 (2012).
45. Krumsiek, J. *et al.* Mining the Unknown: A Systems Approach to Metabolite Identification Combining Genetic and Metabolic Information. *PLoS Genet* **8**, e1003005 (2012).
46. Hartiala, J. A. *et al.* Genome-wide association study and targeted metabolomics identifies sex-specific association of CPS1 with coronary artery disease. *Nat Commun* **7**, 1–10 (2016).
47. Yu, B. *et al.* Loss-of-function variants influence the human serum metabolome. *Sci Adv* **2**, e1600800 (2016).
48. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* **47**, D1005–D1012 (2019).
49. Zhou, Y., Kempson, S. A. & Danbolt, N. C. Betaine Uptake with a Focus on the Betaine/GABA Transporter. in *Betaine: Chemistry, Analysis, Function and Effects* 76–89 (2015).
doi:10.1039/9781782628446-00076.
50. Raffler, J. *et al.* Genome-Wide Association Study with Targeted and Non-targeted NMR Metabolomics Identifies 15 Novel Loci of Urinary Human Metabolic Individuality. *PLoS Genet* **11**, (2015).
51. Wishart, D. S. *et al.* HMDB 4.0: the human metabolome database for 2018. *Nucleic Acids Res* **46**, D608–D617 (2018).
52. Lonsdale, J. *et al.* The Genotype-Tissue Expression (GTEx) project. *Nat Genet* <https://www.nature.com/articles/ng.2653> (2013) doi:10.1038/ng.2653.
53. Gamelin, L. *et al.* Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway. *Clin Cancer Res* **13**, 6359–6368 (2007).
54. Apellániz-Ruiz, M. *et al.* Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy. *Clin Cancer Res* **23**, 1227–1235 (2017).

55. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res* **47**, D506–D515 (2019).
56. Nicholson, G. *et al.* A Genome-Wide Metabolic QTL Analysis in Europeans Implicates Two Loci Shaped by Recent Positive Selection. *PLoS Genet* **7**, (2011).
57. Rueedi, R. *et al.* Genome-Wide Association Study of Metabolic Traits Reveals Novel Gene-Metabolite-Disease Links. *PLoS Genet* **10**, (2014).
58. Schwob, E., Hagos, Y., Burckhardt, G. & Burckhardt, B. C. Transporters involved in renal excretion of N-carbamoylglutamate, an orphan drug to treat inborn n-acetylglutamate synthase deficiency. *Am J Physiol-Renal* **307**, F1373–F1379 (2014).
59. Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association studies. *Nat Genet* **48**, 245–252 (2016).
60. Xu, Z., Wu, C. & Pan, W. Imaging-Wide Association Study: Integrating Imaging Endophenotypes in GWAS. *Neuroimage* **159**, 159–169 (2017).
61. Bentsen, H., Solberg, D., Refsum, H. & Andreassen, O. Redox regulators and oxidative stress in schizophrenia. *Schizophr Bull* **44**, S122 (2018).
62. McClay, J. L. *et al.* Neurochemical metabolomics reveals disruption to sphingolipid metabolism following chronic haloperidol administration. *J Neuroimmune Pharmacol* **10**, 425–434 (2015).
63. Wass, C. *et al.* L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study. *BMC Med* **9**, 40 (2011).
64. Dinc, M. E. *et al.* Thiol/disulfide homeostasis as a novel indicator of oxidative stress in obstructive sleep apnea patients. *Laryngoscope* **127**, E244–E250 (2017).
65. Viau, K. *et al.* Glutaric acidemia Type 1: Outcomes before and after expanded newborn screening. *Mol Genet Metab* **106**, 430–438 (2012).
66. Bowie, C. R. & Harvey, P. D. Cognitive deficits and functional outcome in schizophrenia. *Neuropsychiatr Dis Treat* **2**, 531–536 (2006).

67. Drake, R. E. & Mueser, K. T. Co-Occurring Alcohol Use Disorder and Schizophrenia. *Alcohol Res Health* **26**, 99+ (2002).
68. Bryant, R. Post-traumatic stress disorder vs traumatic brain injury. *Dialogues Clin Neurosci* **13**, 251–262 (2011).
69. Chen, M. *et al.* Proteomic Profiling of Mouse Brains Exposed to Blast-Induced Mild Traumatic Brain Injury Reveals Changes in Axonal Proteins and Phosphorylated Tau. *J Alzheimers Dis* **66**, 751–773 (2018).
70. Martin, C. *et al.* Altered DNA Methylation Patterns Associated With Clinically Relevant Increases in PTSD Symptoms and PTSD Symptom Profiles in Military Personnel. *Biol Res Nurs* **20**, 352–358 (2018).
71. Germain, A. Sleep Disturbances as the Hallmark of PTSD: Where Are We Now? *AJP* **170**, 372–382 (2013).
72. Newgard, C. B. *et al.* A Branched-Chain Amino Acid-Related Metabolic Signature that Differentiates Obese and Lean Humans and Contributes to Insulin Resistance. *Cell Metab* **9**, 311–326 (2009).
73. Cao, H. *et al.* Identification of a Lipokine, a Lipid Hormone Linking Adipose Tissue to Systemic Metabolism. *Cell* **134**, 933–944 (2008).
74. Gillum, M. P. *et al.* N-acylphosphatidylethanolamine, a Gut- Derived Circulating Factor Induced by Fat Ingestion, Inhibits Food Intake. *Cell* **135**, 813–824 (2008).
75. Yore, M. M. *et al.* Discovery of a Class of Endogenous Mammalian Lipids with Anti-Diabetic and Anti-inflammatory Effects. *Cell* **159**, 318–332 (2014).
76. Wang, Z. *et al.* Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* **472**, 57–63 (2011).

77. Wishart, D. S. Emerging applications of metabolomics in drug discovery and precision medicine. *Nat Rev Drug Discov* **15**, 473–484 (2016).
78. Melah, K. E. *et al.* CSF markers of Alzheimer’s pathology and microglial activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer’s disease. *J Alzheimers Dis* **50**, 873–886 (2016).
79. McKhann, G. *et al.* Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. *Neurology* **34**, 939–944 (1984).
80. Jack, C. R. *et al.* Introduction to Revised Criteria for the Diagnosis of Alzheimer’s Disease: National Institute on Aging and the Alzheimer Association Workgroups. *Alzheimers Dement* **7**, 257–262 (2011).
81. Darst, B. F. *et al.* Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid- β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer’s Disease. *J Alzheimers Dis* **55**, 473–484 (2017).
82. Rayner, N. W., Robertson, N., Mahajan, A. & McCarthy, M. I. A Suite Of Programs For Pre- And Post- imputation Data Checking. in (2016).
83. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**, 1284–1287 (2016).
84. Loh, P.-R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat Genet* **48**, 1443–1448 (2016).
85. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* **48**, 1279–1283 (2016).
86. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**, 559–575 (2007).

87. Turner, S. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. *Journal of Open Source Software* **3**, 731 (2018).
88. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
89. Pruim, R. J. *et al.* LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* **26**, 2336–2337 (2010).
90. Frankish, A. *et al.* GENCODE reference annotation for the human and mouse genomes. *Nucleic Acids Res* **47**, D766–D773 (2019).
91. Magno, R. & Maia, A.-T. gwasrapidd: an R package to query, download and wrangle GWAS catalog data. *Bioinformatics* doi:10.1093/bioinformatics/btz605.
92. Chong, J. & Xia, J. MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data. *Bioinformatics* **34**, 4313–4314 (2018).
93. Loo, M. P. J. van der. The stringdist Package for Approximate String Matching. *The R Journal* **6**, 111–122 (2014).
94. Tibshirani, R. Regression Shrinkage and Selection via the Lasso. *J Roy Stat Soc B Met* **58**, 267–288 (1996).
95. Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. *J Roy Stat Soc B* **67**, 301–320 (2005).
96. Hoerl, A. E. & Kennard, R. W. Ridge Regression: Biased Estimation for Nonorthogonal Problems. *Technometrics* **12**, 55–67 (1970).
97. Dudbridge, F. Power and Predictive Accuracy of Polygenic Risk Scores. *PLOS Genet* **9**, e1003348 (2013).
98. Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via Coordinate Descent. *J Stat Softw* **33**, 1–22 (2010).

99. Euesden, J., Lewis, C. M. & O'Reilly, P. F. PRSice: Polygenic Risk Score software. *Bioinformatics* **31**, 1466–1468 (2015).
100. Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat Genet* **1** (2019) doi:10.1038/s41588-018-0311-9.
101. Zhao, Z. *et al.* Fine-tuning Polygenic Risk Scores with GWAS Summary Statistics. *bioRxiv* 810713 (2019) doi:10.1101/810713.
102. Pasaniuc, B. *et al.* Fast and accurate imputation of summary statistics enhances evidence of functional enrichment. *Bioinformatics* **30**, 2906–2914 (2014).
103. Storey, J. D., Bass, A. J., Dabney, A. & Robinson, D. *qvalue: Q-value estimation for false discovery rate control.* (2019).
104. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *eLife* **7**, e34408 (2018).
105. R Core Team. *R: A Language and Environment for Statistical Computing.* (R Foundation for Statistical Computing, 2019).
106. RStudio Team. *RStudio: Integrated Development Environment for R.* (RStudio, Inc., 2018).
107. Wickham, H. *et al.* Welcome to the Tidyverse. *Journal of Open Source Software* <https://joss.theoj.org> (2019) doi:10.21105/joss.01686.